-+ 0.00%
-+ 0.00%
-+ 0.00%

Nanjing Leads Biolabs says NMPA accepts NDA for LBL-024 in advanced EP-NEC

PUBT·08/21/2026 08:42:36
Listen to the news
Nanjing Leads Biolabs says NMPA accepts NDA for LBL-024 in advanced EP-NEC
  • Nanjing Leads Biolabs’ NMPA drug review center accepted an NDA for LBL-024 (Opatlisumab), a PD-L1/4-1BB bispecific, in EP-NEC.
  • The filing targets monotherapy in previously treated advanced extrapulmonary neuroendocrine carcinoma.
  • CDE granted priority review status on July 10, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12293816), on August 21, 2026, and is solely responsible for the information contained therein.